ScoreWhy is Knight Therapeutics, Inc. ?
1
With a growth in Operating Profit of 64.57%, the company declared Outstanding results in Mar 26
- OPERATING CASH FLOW(Y) Highest at CAD 104.53 MM
- NET SALES(Q) Highest at CAD 148.44 MM
- INTEREST COVERAGE RATIO(Q) The company hardly has any interest cost
2
With ROE of 1.37%, it has a expensive valuation with a 1.18 Price to Book Value
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 58.73%, its profits have risen by 127% ; the PEG ratio of the company is 0.7
3
Market Beating performance in long term as well as near term
- Along with generating 58.73% returns in the last 1 year, the stock has outperformed S&P/TSX 60 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Knight Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Knight Therapeutics, Inc. for you?
Medium Risk, High Return
Absolute
Risk Adjusted
Volatility
Knight Therapeutics, Inc.
58.73%
2.40
24.83%
S&P/TSX 60
29.6%
2.31
12.81%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
20.64%
EBIT Growth (5y)
22.85%
EBIT to Interest (avg)
-1.52
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.11
Sales to Capital Employed (avg)
0.46
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.15%
ROCE (avg)
0.11%
ROE (avg)
1.02%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
86
Industry P/E
Price to Book Value
1.18
EV to EBIT
62.90
EV to EBITDA
11.55
EV to Capital Employed
1.20
EV to Sales
1.70
PEG Ratio
0.67
Dividend Yield
NA
ROCE (Latest)
1.91%
ROE (Latest)
1.37%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend37What is working for the Company
OPERATING CASH FLOW(Y)
Highest at CAD 104.53 MM
NET SALES(Q)
Highest at CAD 148.44 MM
INTEREST COVERAGE RATIO(Q)
The company hardly has any interest cost
OPERATING PROFIT(Q)
Highest at CAD 26.77 MM
OPERATING PROFIT MARGIN(Q)
Highest at 18.03 %
RAW MATERIAL COST(Y)
Fallen by -28.17% (YoY
INVENTORY TURNOVER RATIO(HY)
Highest at 2.34 times
DEBTORS TURNOVER RATIO(HY)
Highest at 3.62 times
PRE-TAX PROFIT(Q)
Highest at CAD 16.21 MM
NET PROFIT(Q)
Highest at CAD 15.06 MM
EPS(Q)
Highest at CAD 0.13
-8What is not working for the Company
INTEREST(HY)
At CAD 6.56 MM has Grown at 56.2%
CASH AND EQV(HY)
Lowest at CAD 222.57 MM
Here's what is working for Knight Therapeutics, Inc.
Pre-Tax Profit
At CAD 16.21 MM has Grown at 1,587.27%
over average net sales of the previous four periods of CAD -1.09 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (CAD MM)
Net Profit
At CAD 15.06 MM has Grown at 5,349.06%
over average net sales of the previous four periods of CAD -0.29 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (CAD MM)
Net Sales
Highest at CAD 148.44 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (CAD MM)
Operating Profit
Highest at CAD 26.77 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Operating Profit trend is quite positive
Operating Profit (CAD MM)
Operating Profit Margin
Highest at 18.03 % and Grown
In each period in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Operating Cash Flow
Highest at CAD 104.53 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CAD MM)
Net Sales
At CAD 148.44 MM has Grown at 31.92%
over average net sales of the previous four periods of CAD 112.52 MMMOJO Watch
Near term sales trend is positive
Net Sales (CAD MM)
Pre-Tax Profit
Highest at CAD 16.21 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CAD MM)
Net Profit
Highest at CAD 15.06 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (CAD MM)
EPS
Highest at CAD 0.13
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (CAD)
Inventory Turnover Ratio
Highest at 2.34 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Debtors Turnover Ratio
Highest at 3.62 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -28.17% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Knight Therapeutics, Inc.
Interest
At CAD 6.56 MM has Grown at 56.2%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CAD MM)
Cash and Eqv
Lowest at CAD 222.57 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
